Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Posters/Exhibits/Break > Session
Posters/Exhibits/Break
Presentations
A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION | |||||
|
(700) IMANIXIL-MEDIATED DISRUPTION OF LIPID TRAFFICKING IMPAIRS HEPATIC HEMOGLOBIN CLEARANCE IN SICKLE CELL DISEASE AYYANAR SIVANANTHAM1, NANDHINE RAJASEKAR2, MARTA WOLOSOWICZ1, NICHOLAS SWENDROWSKI1, TIRTHADIPA PRADHAN-SUNDD2,3. 1Thrombosis and Hemostasis Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI, USA 2Transfusion Medicine, Vascular Biology and Cell Therapy Program, Versiti Blood Research Institute, Milwaukee, WI, USA 3Department of Cell Biology, Neurobiology and Anatomy, Medical college of Wisconsin, Milwaukee, WI, USA |
||||
A4. DISORDERS OF PLATELET NUMBER OR FUNCTION | |||||
|
(701) EFFICACY AND SAFETY OF CAPLACIZUMAB IN THROMBOTIC THROMBOCYTOPENIC PURPURA: A SYSTEMATIC REVIEW AND META-ANALYSIS Ursula Medeiros Araujo de Matos1, Pedro Luiz Lage Bodour Danielian2, Ritika Vankina3. 1Internal Medicine Department, University of Connecticut, Farmington, CT, USA 2Harvard T. H. Chan School of Public Health, Boston, MA, USA 3Hematology Oncology Department, University of Connecticut, Farmington, CT, USA |
||||
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS | |||||
|
(702) INNATE IMMUNE CELL ACTIVATION IS ASSOCIATED WITH ANAPHYLACTIC OUTCOMES IN FACTOR IX EXPOSED HEMOPHILIA B MICE Huong Chau, Elizabeth York, Athena S Aragon, Veronica Gonzalez-Pena, Charles Gawad, Glaivy Batsuli. Stanford University, Palo Alto, CA, USA |
||||
|
(703) DETERMINATION OF REGV131-LNP1265-DERIVED HUMAN FACTOR IX ACTIVITY USING ONE-STAGE CLOTTING AND CHROMOGENIC SUBSTRATE ASSAYS: RESULTS FROM A COMPARATIVE FIELD STUDY Karoline A. Meagher1, Robert J. Durso1, KehDih Lai1, Dan Chalothorn1, Natalie Niepoth1, Shane McCarthy1, Sara Hamon1, David E. Gutstein1, Meagan P. O’Brien1, Stefan Tiefenbacher2, William Pickering2, Mary Robinson3, Michael E. Burczynski1. 1Regeneron Pharmaceuticals, Inc., Tarrytown, NJ, USA 2Colorado Coagulation, Laboratory Corporation of America Holdings®, Englewood, CO, USA 3Colorado Coagulation, Laboratory Corporation of America Holdings® (at the time of the study), Englewood, CO, USA |
||||
|
(704) DETECTION OF CONTACT PATHWAY BIOMARKERS IN ECMO PATIENT PLASMA TO ASSESS DEVICE-ASSOCIATED THROMBOSIS Jenny Si Han Wang1, Rosemary B. Falama2, Helen H. Vu3, Cristina Puy1, Owen J. T. McCarty1, Joseph J. Shatzel1,3,4. 1Department of biomedical engineering, Portland, OR, USA 2Department of medicine, Portland, OR, USA 3Knight Cancer Institute, Portland, OR, USA 4Division of Hematology and Medical Oncology, Portland, OR, USA |
|||||
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS | |||||
|
(705) VENOUS THROMBOEMBOLISM AND BLEEDING IN ADVANCED MELANOMA: A PROPENSITY-MATCHED COHORT ANALYSIS COMPARING FIRST-LINE IMMUNOTHERAPY AND TARGETED THERAPY Furkan Bahar1, Lauren O’Loughlin2, Soravis Osataphan2, Reed Drews2, Rushad Patell2. 1Department of Internal Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA 2Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA |
||||
|
(706) OUTCOMES BY DOSE ESCALATION CRITERIA IN PARTICIPANTS WITH HEMOPHILIA A OR B WITHOUT INHIBITORS RECEIVING MARSTACIMAB IN THE BASIS TRIAL Laurent Frenzel1, Travis Gould2, Pengling Sun3, Andrew Palladino4, Oliver Glass3. 1Department of Haematology, Hemophilia Care and Research, Necker Hospital, Institut Imagine, Paris, France 2Pfizer Inc, New York, NY, USA 3Pfizer Inc, Cambridge, MA, USA 4Pfizer Inc, Collegeville, PA, USA |
||||
|
(707) SAFETY AND EFFICACY OF PDVWF/FVIII 1:1 PROPHYLAXIS IN CHILDREN UNDER 6 YEARS WITH SEVERE VWD: RESULTS FROM THE WIL-33 STUDY Akshat Jain1, Cindy Leissinger2, Vladimir Vdovin3, Pavel Zharkov4, Leonid Dubey5, Valentin Ţurea6, Zorica Trajkova Antevska7, Ester Zapotocka8, Bohumír Blažek9, Susan Halimeh10, Amanda Rodriguez11, Tarja-Elina Weisz12, Cristina Solomon13, Robert F. Sidonio Jr14. 1Medical Director Hemophilia Treatment Center, Loma Linda University School of Medicine, Loma Linda, CA, USA 2Tulane University, New Orleans, LA, USA 3Morozovskaya Children’s Hospital, Moscow, Russia 4Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia 5Communal Institution of Lviv Regional Council, Western Ukrainian Specialized Children’s Medical Centre, Lviv, Ukrenia 6IMSP Mother and Child Institute, Chișinău, Moldova 7ERASE Zorica Trajkova Antevska, PHI University Clinic for Child Diseases, Skopje, Moldova 8Department of Pediatric Hematology and Oncology, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic 9University Hospital Ostrava, Ostrava, Czech Republic 10Gerinnungszentrum Rhein Ruhr, Duisburg, Germany 11Octapharma US, Paramus, NJ, USA 12Octapharma Pharmazeutika Produktionsgesellschaft m.b.H,, Vienna, Austria 13Octapharma AG, Clinical Research and Development and Clinical Operations Haematology, Lachen, Switzerland 14Professor of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA |
||||
|
(708) EVALUATING PEN-INJECTOR HANDLING AND PROS IN PATIENTS SWITCHING FROM EMICIZUMAB TO MIM8 IN FRONTIER5 Johnny Mahlangu1, Sanjay Ahuja2, Erin Cockrell3, Víctor Jiménez-Yuste4, Michele Schiavulli5, Amalie Rhode Høgh Nielsen6, Camila Martins Mazini Tavares6, Emily Waters7, Cédric Hermans8, Dan Johnson7. 1Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa 2Indiana Hemophilia & Thrombosis Center, Innovative Hematology, Indianapolis, IN, USA 3Pediatric Hematology Oncology, Saint Joseph’s Children’s Hospital, Tampa, FL, USA 4Hematology Department, La Paz University Hospital, Hospital La Paz Institute for Health Research, Universidad Autónoma Madrid, Madrid, Spain 5Santobono-Pausilipon, Children’s Hospital A.O.R.N., Centro Regionale Pediatrico Malattie della coagulazione, Naples, Italy 6Novo Nordisk A/S, Søborg, Denmark 7Novo Nordisk Inc., Plainsboro, NJ, USA 8Division of Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium |
||||
|
(709) PERFORMANCE EVALUATION, PRECISION AND METHOD COMPARISON OF A NOVEL AUTOMATED COAGULATION ANALYZER Gabrielle Pearl, Lisa Meadows, Vickie Simmons, Mary Knighten, LaShanta Brice, Paul Riley. Diagnostica Stago, Inc., Parsippany, NJ, USA |
||||
|
(710) RURIOCTOCOG ALFA PEGOL USE IN IMMUNE TOLERANCE INDUCTION: AN ANALYSIS OF A PHASE 3 STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A Robert F. Sidonio, Jr.1, Flora Peyvandi2,3, Rachel S. Bercovitz4, Seoh Leng Yeoh5, Zulaiha Muda6, Phu Quoc Le7, Veerle Mondelaers8, Jiaan-Der Wang9, Rashid Kazmi10, Bülent Zülfikar11, Joan Gu12, Srilatha Tangada12. 1Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 3Department of Pathophysiology and Transplantation, Universitàdegli Studi di Milano, Milan, Italy 4Department of Pediatrics, Northwestern University Feinberg School of Medicine, and Division of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA 5Department of Pediatrics, Hospital Pulau Pinang, Penang, Malaysia 6Paediatric Department, Hospital Tunku Azizah Women Children Hospital, Kuala Lumpur, Malaysia 7Hémato-Oncologie, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium 8Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent University, Ghent, Belgium 9Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan 10University Hospital Southampton, Southampton, United Kingdom 11Department of Paediatric Haematology/Oncology, Istanbul University Oncology Institute, Istanbul, Turkey 12Takeda Development Center Americas, Inc., Cambridge, MA, USA |
||||
|
(711) PHARMACOKINETICS OF PLASMINOGEN, HUMAN-TVMH IN SUBJECTS WITH PLASMINOGEN DEFICIENCY TYPE 1 Karen Thibaudeau1, Joseph Parker2, Pierre Chelle3, Andrea Edginton3, Amy Shapiro4. 1Kedrion Biopharma Inc, Laval, QC, Canada 2Kedrion Biopharma Inc, Fort Lee, NJ, USA 3University of Waterloo, Waterloo, ON, Canada 4Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA |
||||
A7. PATHOPHYSIOLOGY OF THROMBOSIS | |||||
|
(712) PROFILING OF EXTRACELLULAR VESICLES AND THROMBO-INFLAMMATORY BIOMARKERS IN PATIENTS WITH PULMONARY EMBOLISM Prakasha Kempaiah1, Mira Nigudkar1, Martin Lundy1, Fahika Siddiqui1, Chongyu Zhang1, Bulent Kantarcioglu1, Debra Hoppensteadt1, Jeanine Walenga1, Thao Doan2, Jawed Fareed1, Amir Darki3, W. Keith Jones 1. 1Loyola University Stritch School of Medicine, Chicago, IL, USA 2AbbVie, North Chicago, Illinois, USA, Chicago, IL, USA 3Division of Cardiovascular Disease and Department of Internal Medicine, Loyola University Chicago, Chicago, IL, USA |
||||
A8. ANTITHROMBOTIC THERAPY | |||||
|
(713) MULTIMODAL DEEP LEARNING FOR PULMONARY EMBOLISM SCREENING USING CHEST X-RAY AND ELECTROCARDIOGRAM DATA Awan Afiaz1,2, Stephen Salerno2, Somin M Lee3, Asher Mendelson4, Barret Rush5, Matthew Samuel5, Max Tang6, Takeshi Tohyama7, Jennifer Ziegler8, Leo A Celi9,10,11, Jeffrey T Leek1,2, Barbara Lam12. 1Department of Biostatistics, University of Washington, Seattle, WA, USA 2Public Health Sciences, Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA 3University of Toronto, Toronto, ON, Canada 4Section of Critical Care, Department of Medicine, University of Manitoba, Winnipeg, MB, Canada 5Massachusetts Institute of Technology, Cambridge, MA, USA 6University of Waterloo, Waterloo, ON, Canada 7Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA 8Department of Medicine, University of Manitoba, Winnipeg, MB, Canada 9Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, MA, USA 10Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA 11Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA 12Division of Hematology/Oncology, Department of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA |
||||
|
(714) THE SENTINEL ROLE OF THE PATHOLOGIST IN DISTINGUISHING BIVALIRUDIN OVERDOSING FROM CONTAMINATION IN PEDIATRIC PATIENTS ON ECLS Vadim Kostousov1, Karen Bruzdoski1, Jun Teruya1, 2, 3. 1Department of Pathology & Immunology, TCH, BCM, Houston, TX, USA 2Department of Pediatrics, TCH, BCM, Houston, TX, USA 3Department of Medicine, TCH, BCM, Houston, TX, USA |
||||
|
(715) A SINGLE-CENTER ANALYSIS OF BIVALIRUDIN INFUSION RATES IN PEDIATRIC PATIENTS REQUIRING SYSTEMIC ANTICOAGULATION FOR TREATMENT OR PREVENTION OF THROMBOSIS. Jennifer Pak1, Kristin Maher2, Kiara Light1, Karyl Kanada2, Nabiha Huq Saifee3, Gavin Roach2. 1Department of Pharmacy, Seattle Children’s Hospital, Seattle, WA, USA 2Division of Hematology-Oncology, Seattle Children’s Hospital, Seattle, WA, USA 3Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA |
||||
A9. INFORMATIONAL ABSTRACT (POSTER ONLY) | |||||
|
(716) OPTIMIZING TRANSCUTANEOUS AURICULAR NEUROSTIMULATION THERAPY FOR HEAVY MENSTRUAL BLEEDING: AN OPEN LABEL TRIAL Christopher J. Czura1, Angela C. Weyand2, Maureen K. Baldwin3, Michael Recht4,5, Caroline Benner1, Kimiko Harada1, Brooke Wade1, Meghan Luellen1, Melanie A. McWade1, Alejandro Covalin1, Navid Khodaparast1. 1Spark Biomedical, Inc., Dallas, TX, USA 2University of Michigan Medical School, Ann Arbor, MI, USA 3Oregon Health Sciences University, Portland, OR, USA 4Yale School of Medicine, New Haven, CT, USA |
||||
|
(717) ANTICOAGULATION PRACTICES IN ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE CHART REVIEW Anthony Liang, Adam Cuker, Pardis Niami. Hospital of the University of Pennsylvania, Philadelphia, PA, USA |
||||
|
(718) DEVELOPMENT OF A MULTIDISCIPLINARY PROGRAM FOR THE PREVENTION OF VENOUS THROMBOSIS IN AMBULATORY PATIENTS WITH CANCER Jocelyn Veals1, Kendra Prasad1, Andrea Cervi1,2. 1Schulich School of Medicine & Dentistry, London, ON, Canada 2Department of Medical Oncology, Windsor Regional Cancer Center, Windsor, ON, Canada |
||||